Today I’d like to discuss a serious topic: the quality issues of domestic pharmaceuticals. I have heard several interesting remarks about domestic drugs, all from practicing doctors. One doctor said that for cardiovascular medications, domestic versions are acceptable in summer, but carry higher risks in winter, when imported drugs are absolutely necessary. Another doctor suggested taking imported medicine at the early stage of illness and switching to domestic alternatives once the condition stabilizes. A third doctor pointed out that ordinary patients have limited medical insurance coverage and can only afford domestic drugs, while retired senior cadres enjoy far higher, nearly uncapped medical benefits. Consequently, inpatient wards for senior cadres in his hospital exclusively use imported medicines.

Professionals in the pharmaceutical industry hold different views. They generally maintain that the overall quality of domestic drugs is acceptable, especially those manufactured in recent years. Nevertheless, they admit that a small number of substandard domestic products do exist. These bad apples have eroded trust in domestic pharmaceuticals among doctors and patients, forcing the entire industry to bear collective blame.

It is understandable for pharmaceutical practitioners to defend their sector. So what is the actual quality level of domestic medicines? First, let us clarify the scope of discussion. The term “domestic drugs” here specifically refers to oral solid tablets and capsules, the most common oral medications that dominate the pharmaceutical market and contain small‑molecule active ingredients. Injectable drugs, biological agents, and traditional Chinese medicines are excluded from this analysis, as the latter generally have no clear division between domestic and imported variants.

It is also critical to distinguish between “imported drugs” and “domestic drugs.” Many so‑called imported medicines are actually produced by Sino‑foreign joint ventures in China. Though domestically manufactured in the strict sense, they follow international production standards, bear foreign pharmaceutical brands, and are priced and categorized as imported products in hospitals and public perception. For this reason, they are classified as imported drugs in this article. The “domestic drugs” discussed here solely refer to products manufactured by state‑owned pharmaceutical enterprises.

Additionally, this discussion only covers medicines produced by formal, licensed manufacturers. Counterfeit drugs from unregulated, unlicensed workshops will not be addressed. While counterfeit medicine cannot be ruled out entirely, openly sold fake drugs are extremely rare in modern China. Reputable urban pharmacies only stock legitimate pharmaceuticals, and store managers face immediate criminal charges if caught selling counterfeits. Such incidents trigger intense public outrage and are handled with severe, expedited penalties, reflecting strict oversight by China’s drug regulatory authorities.

How many types of domestic oral medicines are currently available? According to statistics from the former China Food and Drug Administration, China holds a total of 189,000 drug approval numbers, including 122,000 chemical medicines, over 95% of which are generic drugs. In short, the vast majority of domestic pharmaceuticals on the Chinese market are generics. The core question thus narrows down to: where do domestic generic tablets fall short in quality?

Are generic drugs truly inferior in quality? Official government documents offer a clear answer. On February 13, 2012, the State Council issued the 12th Five‑Year Plan for National Drug Safety, which explicitly stated that “the quality of some generic drugs lags significantly behind advanced international standards.” The plan mandated quality consistency evaluations for generics approved prior to the 2007 revision of the Drug Registration and Administration Measures. A total of 570 essential and widely used chemical medicines, covering 2,400 manufacturers and 33,000 approval numbers (over 90% issued before 2007), were required to complete evaluations by 2015.

In plain terms, the quality of generics approved before 2007 was never systematically verified. Quality varied wildly, with no official guarantee—patients relied entirely on luck. The government acknowledged this critical flaw and launched a nationwide reassessment of pre‑2007 generics, a complex, phased initiative whose first phase was only scheduled for completion by 2015. As a result, the quality of many domestic drugs in current circulation, especially those with pre‑2007 approval licenses, remains unregulated and unreliable.

For further evidence, consider data from the WHO Statistical Yearbook 2009. Only 6 Chinese pharmaceutical products qualified for WHO procurement lists, compared to 194 from India. This massive gap stems from the failure of most Chinese generics to meet WHO quality specifications. Notably, the majority of WHO‑procured medicines are distributed across Africa, giving rise to a widely circulated anecdote: even African refugees refuse Chinese domestic drugs.

Though seemingly absurd, this claim holds substantial merit.

Many may find this perplexing. China is a global manufacturing powerhouse, often dubbed the “king of copycat production.” While the nickname is unflattering, it reflects the nation’s world‑renowned capability for reverse engineering and replication—a skill that is not inherently negative. China also boasts the world’s largest generic drug market, with an annual market value nearing 500 billion RMB. Yet why do Chinese generics lag far behind those of India, a country often underestimated in manufacturing? To answer this, we must first examine the history of generic pharmaceuticals.

Generic drugs are uniquely specialized commodities defined by two irreplaceable attributes. First, identical medications from different manufacturers must deliver consistent quality and efficacy. Unlike gasoline, which is graded and priced differently, tiered quality for pharmaceuticals is ethically unacceptable. Second, the pharmaceutical industry is heavily regulated: drugs require rigorous approval for market entry, and pricing is restricted under medical insurance policies. Decades ago, failure to recognize these unique traits stalled the development of the global generic drug industry. Progress only accelerated after the United States passed the Drug Price Competition and Patent Term Restoration Act of 1984, which resolved core industry contradictions and unified regulatory standards. The year 1984 is therefore widely regarded as the starting point of the modern generic drug era.

Fundamentally, this landmark legislation balanced two conflicting priorities in the pharmaceutical sector: encouraging medical innovation and safeguarding public welfare. On one hand, strong patent protection and exclusive market rights are essential to reward pharmaceutical innovation; without high profit incentives, research and development for new medications would cease. On the other hand, excessive patent protection leads to exorbitant drug prices, placing essential medicines out of public reach. Unlike consumer goods such as televisions—where unaffordability is a personal choice—medicines are public necessities covered by medical insurance, making inflated pricing socially and politically untenable.

The 1984 Act contains complex provisions, but its core significance for generics lies in establishing a universal standard to measure therapeutic equivalence between generic copies and brand‑name patented drugs. As previously noted, pharmaceuticals cannot be graded by quality. Generics may only enter the market after proving they are equally safe and effective as reference brand‑name drugs. Brand‑name medications undergo rigorous Phase I–III clinical trials to verify safety and efficacy, but repeating full clinical trials for every generic duplicate would be wasteful and unnecessary. After consulting global experts, the U.S. FDA designated bioequivalence testing as the definitive evaluation benchmark, drastically cutting R&D costs for generic manufacturers.

What is bioequivalence? Simply explained, the therapeutic effect of a patented drug derives from its active small‑molecule compound. A generic drug is deemed bioequivalent if its active ingredient shares an identical molecular formula and crystal structure, and exhibits nearly identical absorption, distribution and metabolic patterns in human blood. The 1984 Act mandates mandatory bioequivalence testing for all generics seeking market approval. Once certified, generics are recognized as fully interchangeable with brand‑name counterparts. However, a senior expert at China’s National Center for Drug Evaluation revealed that Chinese regulators and medical professionals lack a clear understanding of generic drug standards. Many mistakenly believe generics and brand‑name drugs follow different therapeutic criteria, resulting in widespread clinical distrust of domestic generics.

In contrast, Western regulatory frameworks triggered the “patent cliff” phenomenon. In the United States, brand‑name drug prices plummet immediately once patents expire, as low‑cost, bioequivalent generics flood the market. Pharmacists freely prescribe generics, and medical insurers actively encourage their use to reduce healthcare expenditure. Faced with unbeatable generic competition, most brand‑name manufacturers either slash prices to unprofitable levels or discontinue mature products entirely, reallocating resources to new drug research. This regulatory model achieves dual success: fostering innovation while lowering drug costs and protecting public interests.

Yet the patent cliff has never materialized in China. Imported brand‑name medicines retain their original high prices long after patent expiration and receive preferential “exclusive pricing” in government bidding processes. Consequently, imported medicines in China often cost several times more than domestic generics. To distinguish off‑patent imported brand products from local copies, the Chinese pharmaceutical industry coined the unique term original research drugs—a classification nonexistent overseas. Globally, only two categories exist: patented brand drugs and generics, differentiated solely by patent status yet held to identical quality standards.

Having addressed theoretical flaws in domestic generics, we now examine technical shortcomings. Bioequivalence remains the gold standard for generic quality assessment, relying on two core requirements: identical active pharmaceutical ingredients (APIs) and consistent in‑vivo absorption behavior.

The active small‑molecule compound, professionally termed the active pharmaceutical ingredient (API) or raw material drug, is the foundation of all generics. Decades ago, when imported medicines were scarce in China, domestic chemists synthesized pharmaceutical compounds using published chemical formulas from international literature, marking the birth of China’s generic drug industry. Though complex, API synthesis was mastered through collective research by Chinese chemists, and domestic manufacturers now produce chemical raw materials at scale.

However, multi‑step chemical synthesis inevitably produces byproducts and impurities if purification and reaction processes are incomplete. Poor impurity control was once a major flaw in Chinese generic production, though strict regulatory crackdowns have largely resolved this issue in recent years.

China is a major global exporter of pharmaceutical raw materials, yet this does not equate to competitive generic drug production. APIs are classified as chemical industrial products, not finished pharmaceuticals, and account for a minimal share of final drug value. Low‑cost Chinese raw materials are sold to pharmaceutical manufacturers in Europe, America, India and Israel, who process them into finished medicines and resell them globally at substantial markups. China remains trapped at the lowest end of the global pharmaceutical supply chain as a raw material supplier, while India dominates high‑value generic production.

A hidden downside of raw material production is severe industrial pollution. High pollution treatment costs deter Western manufacturers, who outsource highly polluting raw material processing to China. This arrangement concentrates environmental harm domestically while transferring high profits to foreign enterprises.

API raw materials alone do not constitute usable medicine. To become marketable oral tablets, raw ingredients must be combined with pharmaceutical excipients to form stable solid formulations capable of withstanding transportation, storage and environmental fluctuations.

After ingestion, oral tablets must disintegrate in the digestive tract, release active ingredients, and be absorbed into the bloodstream. Excessively slow dissolution results in incomplete absorption and reduced efficacy. Overly rapid dissolution may trigger side effects or shorten drug duration. This critical digestive absorption process is precisely what bioequivalence testing evaluates.

Standard bioequivalence trials recruit around 20 healthy young adult volunteers. Participants take reference brand drugs and generic test drugs at separate intervals, with regular blood tests to measure drug concentration over time and generate plasma concentration‑time curves. Generics are certified as bioequivalent if their concentration curves differ from brand‑name references by less than 20%. While simplified here, this benchmark ensures consistent in‑vivo performance.

Human bioequivalence trials are costly, leading to the widespread adoption of in vitro dissolution testing as a low‑cost alternative. This method simulates human gastrointestinal conditions at a constant 37°C, measuring tablet dissolution rates in controlled solutions for direct comparison with original research drugs. Though in vitro testing cannot fully replicate individual physiological differences, it serves as an affordable, convenient tool for routine production quality control, while bioequivalence trials remain the international gold standard.

Many consumers question whether minor differences in dissolution rates can meaningfully impact efficacy. The answer is yes, primarily due to opaque gaps in manufacturing technology. Brand‑name pharmaceutical companies publicly disclose molecular formulas but tightly guard production processes. Generic manufacturers rely on reverse engineering to replicate production techniques, yet precise process replication demands advanced industrial expertise and systematic engineering capabilities far beyond basic chemical synthesis. This sophisticated manufacturing know‑how is the key bottleneck holding back Chinese generics. While China excels at replicating consumer goods, pharmaceuticals require refined industrial precision and process control capabilities that remain underdeveloped domestically.

Similar quality gaps exist across other domestic manufacturing sectors, such as passenger vehicles. However, pharmaceuticals differ fundamentally from consumer goods: substandard cars may sell at low prices, but compromised drug quality endangers public health and cannot be normalized.

A senior pharmaceutical engineer offered a vivid analogy: manufacturing medicines is like steaming buns. Identical flour, yeast and cooking equipment do not guarantee identical results. Poor craftsmanship can produce dense, inedible dough lumps despite identical raw materials. In the past, Chinese drug regulators only inspected final chemical compositions when approving generics, overlooking critical processing differences that determine real‑world efficacy.

The root cause of China’s flawed generic drug industry traces back to regulatory failures under former drug administration director Zheng Xiaoyu. Following China’s WTO accession in 2001, strict international patent rules banned unauthorized copying of brand‑name drugs, pushing domestic manufacturers toward generic production. In 2002, the former State Drug Administration issued China’s first comprehensive Drug Registration and Administration Measures, triggering an era of reckless license applications. Manufacturers rushed to secure as many drug approval numbers as possible, with regulatory approvals peaking in 2006. Over four years, excessive licensing created long‑term systemic risks, culminating in Zheng Xiaoyu’s conviction and execution for corruption.

This flawed 2002 regulation contained severe loopholes. While mandating basic testing for oral solid generics, it set excessively lenient bioequivalence standards and allowed flexible reference drug selection. Unlike international rules requiring direct comparison with original patented drugs, Chinese regulations permitted new generics to reference previously approved domestic generics. Cumulative 20% tolerance gaps across successive generic replications created massive deviations from original brand‑name efficacy after multiple generations of copying.

Worse still, loose approval protocols enabled rampant regulatory manipulation and fraud, allowing unqualified manufacturers to obtain production licenses with minimal oversight. Statistics show that 95% of China’s 189,000 drug approval numbers were issued before 2007, held by nearly 5,000 domestic pharmaceutical factories. Most manufacturers hold dozens of licenses, with dozens or even hundreds of companies producing identical medications. Fierce cutthroat bidding competition forces manufacturers to slash production costs to survive, simply switching to alternative drug licenses when profit margins collapse.

This fragmented, overcrowded pharmaceutical landscape is unique to China, with far more manufacturers than any other nation. Excessive competition, often cited as beneficial for consumers, proves destructive in the highly regulated pharmaceutical sector. China’s centralized bidding and medical insurance pricing system compresses drug prices to unsustainably low levels. Local protectionism further distorts competition, as regional bidding policies reserve fixed shares for local manufacturers. Combined with lax national quality standards, manufacturers inevitably sacrifice quality to cut costs—a crisis epitomized by the toxic capsule scandal, where marginal cost savings became the only viable profit strategy.

Public outrage over toxic capsules overlooks a far more critical issue: severe bioequivalence discrepancies between domestic generics and imported original drugs. Many domestic tablets fail to disintegrate or dissolve adequately in the digestive tract, passing through the body without releasing active ingredients. This widespread ineffective absorption is the primary cause of poor domestic drug quality. Ironically, consumers continue to demand lower drug prices without recognizing the inevitable trade‑off with quality. Domestic drug prices themselves are reasonably low; inflated medical expenditure stems primarily from China’s hospital financing model reliant on pharmaceutical sales, not excessive pricing by drug manufacturers.

The Chinese government is fully aware of these systemic issues, and the ongoing generic drug quality consistency evaluation initiative represents a long‑overdue regulatory correction. Nevertheless, implementation progress has been slow and constrained by economic realities. Local pharmaceutical factories are major tax contributors and large employers across regions. Mass shutdowns of unqualified manufacturers would trigger mass unemployment and social unrest, creating strong local resistance to strict reform. Industry insiders summarize the dilemma with a pointed metaphor: authorities tolerate public complaints over substandard medicine to prevent far more destabilizing social unrest from mass layoffs.

Ultimately, the crisis reflects poorly coordinated relationships between the government, domestic enterprises and consumers. Taiwan faced identical challenges in the early 1980s, but resolute regulatory leadership slashed local pharmaceutical manufacturers from 550 to 163 within years, drastically raising generic drug quality through strict consolidation and higher standards.

Reform is undoubtedly far more complex in mainland China, with deeper institutional and regional barriers to change. Even so, medicines are irreplaceable public goods critical to national health and fiscal stability, with enormous future market potential. As a vital strategic industry, pharmaceuticals could serve as a pilot for in‑depth industrial reform, setting a benchmark for other sectors. For now, all that remains is to wait and see.